Drug Profile

Research programme: matrix metalloproteinase 13 inhibitors - H. Lee Moffitt Cancer Center and Research Institute/Florida Atlantic University Research Corporation/SteroTherapeutics

Latest Information Update: 06 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Florida Atlantic University Research Corporation; H. Lee Moffitt Cancer Center and Research Institute
Developer Florida Atlantic University Research Corporation; H. Lee Moffitt Cancer Center and Research Institute; SteroTherapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Matrix metalloproteinase 13 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Mar 2022 Matrix metalloproteinase 13 inhibitors licensed to SteroTherapeutics
30 Mar 2022 Early research in Multiple myeloma in USA (unspecified route), before March 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com